JKJohanna Louise Keeler

Johanna Louise Keeler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johanna Louise Keeler has a total of 144 co-authors. Here are the top co-authors by number of shared publications:

  • Hubertus Himmerich

    King’s College London

    25 shared publications
  • Janet Treasure

    Department of Psychological Medicine Institute of Psychiatry, Psychology and Neuroscience, King's College London London UK

    23 shared publications
  • Janet Treasure

    Centre for Research in Eating and Weight Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, the United Kingdom of Great Britain and Northern Ireland; South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent BR3 3BX, the United Kingdom of Great Britain and Northern Ireland

    10 shared publications
  • Hubertus Himmerich

    Department of Psychological Medicine, Centre for Research in Eating and Weight Disorders, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

    8 shared publications
  • Ulrike Schmidt

    Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK

    7 shared publications
  • Hiba Mutwalli

    Centre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 8AF, UK

    6 shared publications

Latest Publications

  • Remotely-administered app-based pavlovian disgust conditioning in individuals with eating disorders: a proof-of-concept pilot study

    by Sevgi Bektas-Dag, Thomas McGregor, Murat Aksit, Johanna Keeler, Hubertus Himmerich, Janet Treasure, Valentina Cardi

  • Open Access

    Resumption of Menses and Normalisation of Body Weight in Adolescents Undergoing Specialised Treatment for Anorexia Nervosa Inpatient or Outpatient Treatment

    by Annika Woltmann, Linus Imken, Vivien Kaiser, Johanna L. Keeler, Daniel Le Grange, Christoph U. Correll, Verena Haas

    Objective: To predict resumption of menses (ROM) in patients with anorexia nervosa (AN). Method: Females aged 9–17 years with AN, receiving inpatient multimodal treatment (IMT) or family‐based treatment (FBT) underwent assessments at baseline, 6‐month and 12‐month follow‐up (12FU). A menstrual questionnaire recorded date, weight and height at loss of menses (LOM) and ROM occurring up to 30 months after 12FU. A stepwise backward logistic regression analysis evaluated predictors for menstruation at 12FU. Results: Among 99 females (age = 14.8 ± 1.7) with AN (restrictive = 85 [86%], binge‐purge = 8 [8%], atypical = 6 [6%]), and percent median body mass index (%median BMI) = 78.9 [IQR = 74.3, 82.8] undergoing IMT ( n = 50) or FBT ( n = 49), 66 (66.7%) had at baseline secondary amenorrhoea, 26 (26.3%) were without menarche, 5 (5.1%) had regular menses, and 2 (2.0%) used contraceptives. At 12FU, menses were present in 45 (45.5%) patients and associated with baseline menarche (OR = 6.04, p = 0.002) and higher 12FU %mBMI (OR = 1.08, p = 0.006) ( R 2 = 0.251). After an average of 15 months of amenorrhoea [IQR = 12.0, 25.0] ( n = 41 with information), %mBMI at ROM (92.0 [IQR = 86.6, 97.8], equalling BMI percentile = 25.0; range = 1–60), was 6.8 %mBMI units > LOM (85.2 [IQR = 79.9, 92.0]; p = 0.001), and 6.5 %mBMI units < premorbid %mBMI (98.5 [IQR = 94.1109.7]; p < 0.001). Conclusions: ROM follows weight recovery. Full restoration to premorbid BMI percentile is not necessary for ROM.

  • Open Access

    Virtual reality interventions in obesity and eating disorders: a systematic review of biomarker, clinical, and behavioral outcomes

    by Wafa Abdulrahman Alharbi, Johanna Keeler, Yasmin Benbow, Marta Ortega Vega, Nicole Ting, Hubertus Himmerich, Janet Treasure

    Obesity and eating disorders (EDs) are major public health challenges associated with high morbidity and mortality. This systematic review evaluated the effects of immersive virtual reality (VR) interventions on clinical outcomes and biomarker-domain outcomes in obesity and EDs. Following PRISMA 2020 guidelines, PubMed, Web of Science, and PsycINFO were searched through to April 2025. Eligible studies included immersive VR interventions targeting obesity or EDs and reporting at least one biomarker-domain outcome (anthropometric, physiological/autonomic, endocrine/metabolic, or neurocognitive/eye-tracking). Risk of bias was assessed using Joanna Briggs Institute tools. When at least three RCTs reported comparable outcomes, random-effects meta-analyses were performed. Twenty-three studies met the inclusion criteria (11 obesity, 12 EDs). ED studies included anorexia nervosa, bulimia nervosa, and binge-eating disorder. In obesity, VR-enhanced cognitive–behavioral therapy (VR-CBT) was associated with weight-loss maintenance, while VR-based exercise interventions were associated with short-term reductions in BMI and body weight. A meta-analysis of four RCTs showed a significant pooled effect of VR compared with control on anthropometric outcomes (Hedges’ g = − 0.35, 95% CI [–0.61, − 0.09], p = .009; I² = 0%), with a numerically larger effect for VR-CBT. In EDs, VR-CBT was associated with reductions in body image disturbance and fear of weight gain, while VR cue-exposure therapy was linked to decreases in binge and purge frequency. Eye-tracking measures indicated attentional biases toward disorder-relevant cues, and autonomic and endocrine markers suggested VR’s ability to elicit measurable psychophysiological responses. Overall, immersive VR interventions show promising but still preliminary effects across anthropometric, neurocognitive, and selected psychophysiological outcomes in obesity and EDs. Conclusions are constrained by small samples, heterogeneity within the interventions and outcome definitions, and a limited randomized evidence base (particularly in EDs). Larger biomarker-integrated trials with standardized measurement protocols and longer follow-up are needed to confirm efficacy and clarify mechanisms.


  • Open Access

    Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study

    by Ece Sengun Filiz, Dominic Stringer, Vanessa Kellermann, Rachel Rowan Olive, Olena Said, Hiba Mutwalli, Sevgi Bektas, Melahat Nur Akkese, Katie Ireland, Demelza Beishon-Murley, et al.

    Background: In clinical practice, olanzapine is commonly used in young people with anorexia nervosa, although the underpinning evidence-base is limited. However, its efficacy, tolerability, acceptability and adherence rate, and the patients’, carers’ and clinicians’ views of olanzapine treatment are unclear. This synopsis article summarises the methods and results of the OPEN feasibility study, overarching the findings and drawing comprehensive conclusions from a quantitative feasibility outcome paper and two qualitative research papers. Methods: The OPEN study assessed the feasibility of a future randomised controlled trial on olanzapine in young people with anorexia nervosa in an open-label, one-armed feasibility study. In this study, we aimed to include 55 patients with anorexia nervosa or atypical anorexia nervosa aged 12–24 who gained < 2 kg within at least 1 month of treatment as usual. Time points for assessments were at baseline, 8 weeks, 16 weeks, and 6 or 12 months. We estimated recruitment, adherence and attrition rates and mean changes in body weight, body mass index and eating disorder psychopathology. In addition, we explored the views on and experiences with olanzapine treatment within a clinical trial setting using qualitative interviews with young people with anorexia nervosa, their families and clinicians. Results: Fifty-two people were pre-screened, 35 were eligible and 20 participants were recruited and started olanzapine. Of these, 15 continued olanzapine for ≥ 16 weeks. Participants experienced, on average, a decrease in their eating disorder psychopathology, and body weight and body mass index increased during treatment with olanzapine as an adjunct to treatment as usual. Important themes derived from semi-structured qualitative interviews with young people and their parents were: moving away from the illness towards recovery, evaluating information on olanzapine, consent and trust in shared decision-making and the ambivalence around recovery. The main themes expressed by clinicians included: acknowledging the concerns of young people with anorexia nervosa and their families, prioritising person-centred care, the limited service capacity and strict study eligibility criteria. Limitations: The study failed to meet the recruitment target and showed low adherence rates for treatment with olanzapine. Possible reasons for the recruitment difficulties and the low adherence rate include the high clinical workload of eating disorder services during and after the COVID-19 pandemic, the heterogeneity of eating disorder service setup across the country, and the reluctance of patients to agree to take olanzapine under the relatively restricted conditions of a clinical study. Conclusions: A realistic time schedule for site-preparation, recruitment, treatment and follow-up, realistic recruitment targets and easy access to medical and laboratory examinations may improve the success of future feasibility studies and randomised controlled trials in this patient group. Future work: The difficulties in conducting the OPEN study will inform the planning for future pharmacological and non-pharmacological studies in anorexia nervosa. Therefore, we developed a checklist with action points for the planning of pharmacological trials in eating disorders. Furthermore, novel pharmacological options such as typical and atypical psychedelic drugs (e.g. psilocybin and ketamine) might be more acceptable for people with anorexia nervosa as they do not have the side effect of immediate weight gain. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR130780.

  • Top Cited Papers
    Open Access

    Associations of Problematic Smartphone Use and Smartphone Screen Time With Eating Disorder Psychopathology in Non-Clinical Samples: A Systematic Review

    by Johanna Keeler, Laura Conde Ludtke, Qingyu Yang, Valentina Raschke Rameh, Rebecca Ward, Janet Treasure, Ben Carter

    Background: The ubiquitous use of smartphones has given rise to maladaptive patterns of use, often termed “problematic smartphone use” (PSU), which disproportionately impacts children and young people and is associated with poor mental health. Emerging evidence suggests that patterns of smartphone use (eg, PSU and high smartphone screen time) may also influence eating patterns and contribute to symptoms associated with eating disorders (ED), although the nature of this relationship remains poorly understood. Objective: The aim of this systematic review was to examine the association between PSU and ED psychopathology or ED-related outcomes (eg, body dissatisfaction, emotional eating, and food addiction) in clinical and nonclinical populations and explore potential moderators and mediators. Methods: This preregistered systematic review conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines searched 3 databases (PubMed, Embase, and Web of Science) for studies published after January 2011 reporting data on PSU and ED psychopathology. Results: Thirty-five studies met the prespecified eligibility criteria, with almost all reporting cross-sectional data in nonclinical populations (n=52,584; mean age 17.0, SD 5.5 years). Most studies were assessed as being of good quality (n=28, 78%) according to a modified version of the Newcastle-Ottawa Scale. In these nonclinical samples, the vast majority of studies reported a positive association between PSU and ED psychopathology, which was largely consistent across age groups and countries. Identified mediators of this relationship included greater emotional regulation difficulties and anxious and depressive symptoms. Positive associations were also found across studies between PSU and several ED-related outcomes including food addiction, body dissatisfaction, uncontrolled eating, and emotional overeating. Daily smartphone screen time was consistently related to higher ED psychopathology. According to a GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) assessment of the evidence, most outcomes were rated as low certainty, largely due to the cross-sectional nature of evidence, which contributed to a high risk of bias. Conclusions: PSU and greater daily smartphone screen time are associated with higher ED symptoms, body image dissatisfaction, and broader disordered eating behaviors. Due to a paucity of studies in clinical populations, these conclusions are generalizable only to nonclinical populations (ie, those without a formal diagnosis of an ED). Further longitudinal research in clinical populations is needed to fully contextualize the impact of PSU and smartphone screen time on ED risk and severity.


  • Open Access

    Perceived carer skills and psychological distress in fathers and mothers of adults with anorexia nervosa: a longitudinal study

    by Melahat Nur Akkese, Johanna Keeler, John Hodsoll, Suman Ambwani, Hubertus Himmerich, Katie Rowlands, Valentina Cardi, Janet Treasure

    Parents often remain the primary carers for their adult children with anorexia nervosa (AN) for an extended time. Carer strain and unhelpful behaviours hav


  • Open Access

    A systematic review and meta-analysis of routine white blood cell concentrations in people with eating disorders

    by Johanna L Keeler, Can Xu, Rebecca Morris, Hannah Hartland, Janet Treasure, Hubertus Himmerich


  • Open Access

    Problematic smartphone use and smartphone screen time are associated with eating disorder psychopathology in non-clinical samples: a systematic review (Preprint)

    by Johanna Keeler, Laura Conde Ludtke, Qingyu Yang, Valentina Raschke Rameh, Janet Treasure, Ben Carter

    BACKGROUND The ubiquitous use of smartphones has given rise to addictive patterns of use, often termed “problematic smartphone use” (PSU), which disproportionately impacts children and young people and is associated with poor mental health. Emerging evidence suggests that patterns of smartphone use (e.g., PSU and high screen time) may also influence eating patterns and contribute to symptoms associated with eating disorders (ED), although the nature of this relationship remains poorly understood. OBJECTIVE The aim of this systematic review was to examine the association between PSU and ED psychopathology or ED-related outcomes (e.g., body dissatisfaction, emotional eating, food addiction) in clinical and non-clinical populations and explore potential moderators and mediators. METHODS This pre-registered systematic review conducted according to PRISMA guidelines searched three databases (PubMed, EMBASE and Web of Science) for studies published after January 2011 reporting data on PSU and ED psychopathology. RESULTS Thirty-six studies met the pre-specified eligibility criteria, with almost all reporting cross-sectional data in non-clinical populations (mean±SD age 17.0±5.5). Most studies were assessed as being of good quality (n = 28; 78%). In these non-clinical samples, the vast majority of studies reported a positive association between PSU and ED psychopathology, which was largely consistent across age groups and countries. Identified mediators of this relationship included greater emotional regulation difficulties, and anxious and depressive symptoms. Positive associations were also found across studies between PSU and several ED-related outcomes including food addiction, body dissatisfaction, uncontrolled eating and emotional overeating. Daily smartphone use was consistently related to higher ED psychopathology. CONCLUSIONS PSU and greater daily screen time are associated with higher ED symptoms, body image dissatisfaction, and broader disordered eating behaviours. Due to a paucity of studies in clinical populations, these conclusions are generalisable only to non-clinical populations (i.e., those without a formal diagnosis of an ED). Further longitudinal research in clinical populations is needed to fully contextualise the impact of PSU and screen time on ED risk and severity.

  • Open Access

    Cytokine concentrations in people with eating disorders: A comprehensive updated systematic review and meta-analysis

    by Johanna L. Keeler, Charlotte Bovenberg, Hubertus Himmerich, Janet Treasure, Ben Carter, Ulrike Schmidt, Bethan Dalton

    Background: Prior research has found altered levels of cytokines in people with eating disorders (EDs). This study is an update of a previous meta-analysis, including longitudinal analyses and machine learning heterogeneity analyses (MetaForest). Methods: This pre-registered (https://osf.io/g6d3f) systematic review and meta-analysis following PRISMA guidelines assessed studies from four databases (PubMed, Web of Science, MEDLINE, PsycINFO) reporting cytokine concentrations in people with EDs until 10th November 2024. Random-effects models were utilised for all meta-analyses. Results: Twenty-four new studies are incorporated, resulting in a total of 43 studies included in meta-analyses. Interleukin (IL)−6 and IL-15 are higher, and IL-7 lower, in anorexia nervosa (AN) compared with controls. When controlling for outliers, tumour necrosis factor (TNF)-α, IL-1β, IL-4, IL-8, IL-10, interferon (IFN)-γ, monocyte chemoattractant protein (MCP) and transforming growth factor (TGF)-β are similar between AN and controls. Longitudinally, IL-6 is lower in AN at follow-up compared to baseline, although this may be an artefact of publication bias. TNF-α and IL-1β do not change longitudinally. There are largely no differences in IL-6 and TNF-α in bulimia nervosa (BN) and there are insufficient studies to perform meta-analyses for binge eating disorder or other EDs. Conclusions: In acute AN, concentrations of IL-6 and IL-15 are elevated and IL-7 is decreased, with preliminary but unconclusive evidence for small decreases in IL-6 over the course of weight restoration. Other cytokines considered to have broadly pro-inflammatory functions are not increased in AN. In BN, there is little evidence for increases in pro-inflammatory cytokines, but the evidence base is limited.


  • Open Access

    Comment on Wu et al. Peripheral Biomarkers of Anorexia Nervosa: A Meta-Analysis. Nutrients 2024, 16, 2095

    by Johanna L. Keeler, Jonas L. Steinhäuser

    The identification of biomarkers is an important precondition for the development of personalised treatments for anorexia nervosa (AN)